Sutro Biopharma

Sutro Biopharma develops protein therapeutics by using OCFS protein synthesis technology.

Sutro Biopharma is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease. Sutro is applying its technology to the development of next-generation, non-native protein structures such as antibody fragments, single-chain antibodies, and other proteins with novel scaffolds. We are also working to provide novel functionalities to our core technology with a goal of further improving the therapeutic benefit of the products we make. Sutro Biopharma, Inc. has a 24,000 sq. ft facility located in South San Francisco, California. Our pilot facility houses 15-Liter fermentors, a 200-L fermentor, and related research, development and downstream activities to support the scale-up of protein therapeutic candidates.